NEWS: SolasCure is delighted to announce that it has been selected to receive the European Innovation Council’s @EUeic Accelerator Grant to continue development of its innovative wound care technology. Read more: #woundcare #chronicwounds #EIC

SolasCure welcome Lee Harle as our Chief Business Officer, responsible for spearheading our market-entry strategy. Lee brings 25+ years’ experience building successful businesses & joint-ventures in consumer goods, technology & life-science industries worldwide.

Generate videos in just a few seconds. Try Grok Imagine, free for a limited time.

SolasCure announces £10.9m Series B fundraise to advance #woundcare innovation. The funding supports development of Aurase Wound Gel, progressing clinical trials of this innovative wound debriding enzyme following completion of the Phase IIa safety study:

SolasCure are delighted to be named a top Biopharma companies in Cambridgeshire. SolasCure’s pioneering aim to develop efficacious wound care products by leveraging maggot enzyme earned a place, alongside the likes of Astra Zeneca & Healx. #woundcare.

SolasCure are delighted to have been selected as a UK Life Sciences Innovator 2023. This is significant recognition by @tradegovukMEAP of our propriety technology as we work to develop revolutionary wound care treatments. #LSI2023 #UKInnovation #LifeSciences #Future #Technology

SolasCure is delighted to announce that CTO Dr Bela Kelety will be speaking at this year’s Pharma Contract Manufacturing conference in Berlin from 28th -30th March, sharing insights on the importance of scaling up for start-ups. @PharmaIQ .#pharmaevents #PCM2023 #biotech

We are delighted that David Fairlamb, Director of Regulatory Affairs at SolasCure, has won the Futures category at the TOPRA awards, which recognises the role of regulatory scientists in realising the potential of cutting-edge technologies. Learn more:

SolasCure's toxicology & pre-clinical research programme has been published in the International Wound Journal, with the enzyme used in Aurase Wound Gel shown to have a good safety profile. Read more: #woundcare #IWJ #chronicwounds

Meet Oliver Schofield, Chief Financial Officer at SolasCure. Oliver is an experienced biotech start-up CFO & previously worked in management consulting at KPMG. He is also CIMA certified. Read more about wound care problems SolasCure is looking to solve:

We're delighted to announce that David Fairlamb, Director of Regulatory Affairs at SolasCure, has won the Futures category at the TOPRA awards, recognising the role of regulatory scientists in realising the potential of cutting-edge technologies. Read on:

Meet David Fairlamb, Director of Regulatory Affairs at SolasCure. David has over 30 years of global Regulatory Affairs experience working in industry & consultancy within drug, biologics, medical devices & combination products

Meet Prof. @DavidGoldsmith, Chief Medical Officer at SolasCure. Prof. Goldsmith is a former Emeritus Professor of Cardio-Renal Medicine at the University of London & former Consultant Nephrologist at Guy’s & St Thomas’ NHS Foundation Trust Hospital.

Meet Dr. Kinga Szepeshazi, Chief Development Officer at SolasCure. Dr. Szepeshazi has extensive experience in global clinical studies and was formerly Head of Early Phase Clinical Development at Richter Gedeon & Medical Director at Immunic Therapeutics.

Meet Dr. Bela Kelety, Chief Technology Officer at SolasCure. He is responsible for product development and manufacturing of Aurase Wound Gel. Find out more about Aurase Wound Gel and the problems that SolasCure is looking to solve:

People living with chronic wounds describe the experience as isolating & debilitating. . Our goal is to find a solution to improve the chronic wound patient outcomes in all settings. Find out more about SolasCure:

Meet Dr. Sam Bakri, Founder and CEO at SolasCure. Find out more about Dr. Bakri’s journey as doctor-turned-entrepreneur and his mission to meet the unmet need in treating chronic wounds:

Chronic wounds have a severe impact on patients’ quality of life & can lead to social isolation, anxiety and depression. . SolasCure is developing a pioneering new treatment. Read more about our revolutionary wound care hydrogel:

By replicating a specific enzyme in maggots’ saliva and combining it with a hydrogel, SolasCure aims to leverage the power of maggots to create a pioneering new treatment that will aim to allow more effective debridement. Read more about our technology:

Meet Dr. Rob Kirsner. He is a leading wound care doctor and the US Medical Advisory Board Chair at SolasCure. Find out more:

SolasCure has been named the winner of the #biotech category at the EIT Health Catapult finals in Stockholm. The medical use of Aurase Wound Gel is being developed with the aim of accelerating wound debridement, by leveraging #biomimicry. Read more: